QLT maintained by Merrill at buy

QLT Inc. was maintained by Merrill Lynch analyst Hari Sambasivam at a buy rating with a price target of $17 per share, following its joint announcement jointly with partner Novartis AG of an 18% rise in second quarter Visudyne sales of $129 million versus Merrill's estimate of $128 million. QLT shares Thursday rose 7 cents, or 0.66%, to $10.64 on volume of 3 million shares versus the three-month running average of 1.15 million.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.